- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Adello Biologics Submits BLA for Filgrastim Biosimilar
Adello Biologics, a New Jersey-based biosimilar developer previously named Therapeutic Proteins International, announced this week that its Biologics License Application (BLA) for a biosimilar filgrastim candidate has been accepted for review by the FDA.
Adello Biologics, a New Jersey-based biosimilar developer previously named Therapeutic Proteins International, announced this week that its Biologics License Application (BLA) for a biosimilar filgrastim candidate has been accepted for review by the FDA. The company did not disclose a biosimilar user fee action date for a regulatory decision by the FDA.
Peter Moesta, PhD, CEO of Adello said, “If approved, we are excited to be able to offer an additional, important treatment choice that can prevent serious complications for patients.”
Adello’s BLA includes data from a double-blind, single-dose, 2-period crossover pharmacokinetic (PK) and pharmacodynamic (PD) study of its product in comparison with the reference filgrastim. The study, which included 54 healthy volunteers, demonstrated that Adello’s product had similar PK and PD properties to the reference drug. Safety and immunogenicity were also similar between the 2 products.
Reference filgrastim (Amgen’s Neupogen) is a granulocyte colony-stimulating factor used to treat or prevent chemotherapy-induced neutropenia. To date, 1 biosimilar filgrastim, Sandoz’s Zarxio, is available in the United States.
Adello also reported that it is developing a biosimilar pegfilgrastim, referenced on Neulasta, and a biosimilar adalimumab, referenced on Humira, in addition to a number of other products that are currently in preclinical development.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer
February 8th 2025A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
A Banner Year for Biosimilars: The 19 FDA Approvals From 2024
January 21st 2025In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options and market competition.
